OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Cost of Revenue

Last Annual Value

2.78K

3-Year CAGR

-87%

5-Year CAGR

-8%

10-Year CAGR

-4%

OT

OS Therapies Incorporated Competitors Analysis of Cost of Revenue

OSTX · NYSE
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.78K
-13.0%-70.1%N/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
0.00
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
378.61K
N/AN/A38.9%
930.00K
N/AN/AN/A
3.48M
-55.0%N/A32.9%
0.00
N/AN/AN/A
1.63M
-2.5%N/AN/A
21.00K
N/AN/AN/A
4.20M
61.2%N/AN/A
648.00K
406.1%217.8%N/A
1356.33B
31210.3%2101.7%N/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42